Medication treatment strategies in the MTA Study: relevance to clinicians and researchers - PubMed (original) (raw)
Clinical Trial
. 1996 Oct;35(10):1304-13.
doi: 10.1097/00004583-199610000-00017.
H B Abikoff, L E Arnold, D P Cantwell, C K Conners, G Elliott, L Hechtman, S P Hinshaw, B Hoza, P S Jensen, J S March, J Newcorn, W E Pelham, J B Severe, J M Swanson, B Vitiello, K Wells
Affiliations
- PMID: 8885584
- DOI: 10.1097/00004583-199610000-00017
Free article
Clinical Trial
Medication treatment strategies in the MTA Study: relevance to clinicians and researchers
L L Greenhill et al. J Am Acad Child Adolesc Psychiatry. 1996 Oct.
Free article
Abstract
Objective: Clinicians have difficulty applying drug research findings to clinical practice, because research protocols use methods different from those used in daily office practice settings.
Method: To design a medication protocol for a multisite clinical trial involving 576 children with attention-deficit hyperactivity disorder (ADHD) while maintaining relevance to clinical practice, investigators from the NIMH Collaborative Multisite Multimodal Treatment Study of Children with Attention-Deficit/Hyperactivity Disorder (MTA study) developed novel medication strategies. These were designed to work either in a monomodal or multimodal format and to ensure standard approaches are used across diverse sites. Each child randomized to medication (projected N = 288) is individually titrated to his or her "best" methylphenidate dose and has individual ADHD symptoms monitored. Decision rules were developed to guide "best dose" selection, dose changes, medication changes, the management of side effects, and integration with psychosocial treatments.
Conclusions: The MTA study uses a controlled method to standardize the identification of each child's "best" methylphenidate dose in a national, multisite cooperative treatment program. Although the titration protocol is complex, the study's individual dosing approach and algorithms for openly managing ADHD children's medication over time will be of interest to clinicians in office practice.
Similar articles
- Randomized controlled double-blind trial of optimal dose methylphenidate in children and adolescents with severe attention deficit hyperactivity disorder and intellectual disability.
Simonoff E, Taylor E, Baird G, Bernard S, Chadwick O, Liang H, Whitwell S, Riemer K, Sharma K, Sharma SP, Wood N, Kelly J, Golaszewski A, Kennedy J, Rodney L, West N, Walwyn R, Jichi F. Simonoff E, et al. J Child Psychol Psychiatry. 2013 May;54(5):527-35. doi: 10.1111/j.1469-7610.2012.02569.x. Epub 2012 Jun 7. J Child Psychol Psychiatry. 2013. PMID: 22676856 Clinical Trial. - Impairment and deportment responses to different methylphenidate doses in children with ADHD: the MTA titration trial.
Greenhill LL, Swanson JM, Vitiello B, Davies M, Clevenger W, Wu M, Arnold LE, Abikoff HB, Bukstein OG, Conners CK, Elliott GR, Hechtman L, Hinshaw SP, Hoza B, Jensen PS, Kraemer HC, March JS, Newcorn JH, Severe JB, Wells K, Wigal T. Greenhill LL, et al. J Am Acad Child Adolesc Psychiatry. 2001 Feb;40(2):180-7. doi: 10.1097/00004583-200102000-00012. J Am Acad Child Adolesc Psychiatry. 2001. PMID: 11211366 Clinical Trial. - Longer term effects of stimulant treatments for Attention-Deficit/Hyperactivity Disorder.
Jensen P. Jensen P. J Atten Disord. 2002;6 Suppl 1:S45-56. doi: 10.1177/070674370200601s06. J Atten Disord. 2002. PMID: 12685518 Review. - Managing stimulant medication for attention-deficit/hyperactivity disorder.
Wender EH. Wender EH. Pediatr Rev. 2001 Jun;22(6):183-90. doi: 10.1542/pir.22-6-183. Pediatr Rev. 2001. PMID: 11389305 Review. No abstract available.
Cited by
- Current use of attention-deficit hyperactivity disorder (ADHD) medications and clinical characteristics of child and adolescent psychiatric outpatients prescribed multiple ADHD medications in Japan.
Sasaki Y, Tsujii N, Sasaki S, Sunakawa H, Toguchi Y, Tanase S, Saito K, Shinohara R, Kurokouchi T, Sugimoto K, Itagaki K, Yoshida Y, Namekata S, Takahashi M, Harada I, Hakosima Y, Inazaki K, Yoshimura Y, Mizumoto Y, Okada T, Usami M. Sasaki Y, et al. PLoS One. 2021 Jun 3;16(6):e0252420. doi: 10.1371/journal.pone.0252420. eCollection 2021. PLoS One. 2021. PMID: 34081716 Free PMC article. - The challenges of implementing ADHD clinical guidelines and research best evidence in routine clinical care settings: Delphi survey and mixed-methods study.
Hall CL, Taylor JA, Newell K, Baldwin L, Sayal K, Hollis C. Hall CL, et al. BJPsych Open. 2016 Jan 20;2(1):25-31. doi: 10.1192/bjpo.bp.115.002386. eCollection 2016 Jan. BJPsych Open. 2016. PMID: 27703750 Free PMC article. - A clinical review of outcomes of the multimodal treatment study of children with attention-deficit/hyperactivity disorder (MTA).
Murray DW, Arnold LE, Swanson J, Wells K, Burns K, Jensen P, Hechtman L, Paykina N, Legato L, Strauss T. Murray DW, et al. Curr Psychiatry Rep. 2008 Oct;10(5):424-31. doi: 10.1007/s11920-008-0068-4. Curr Psychiatry Rep. 2008. PMID: 18803917 Free PMC article. Review. - Community vs. clinic-based modular treatment of children with early-onset ODD or CD: a clinical trial with 3-year follow-up.
Kolko DJ, Dorn LD, Bukstein OG, Pardini D, Holden EA, Hart J. Kolko DJ, et al. J Abnorm Child Psychol. 2009 Jul;37(5):591-609. doi: 10.1007/s10802-009-9303-7. J Abnorm Child Psychol. 2009. PMID: 19221871 Free PMC article. Clinical Trial. - The MTA at 8 years: prospective follow-up of children treated for combined-type ADHD in a multisite study.
Molina BSG, Hinshaw SP, Swanson JM, Arnold LE, Vitiello B, Jensen PS, Epstein JN, Hoza B, Hechtman L, Abikoff HB, Elliott GR, Greenhill LL, Newcorn JH, Wells KC, Wigal T, Gibbons RD, Hur K, Houck PR; MTA Cooperative Group. Molina BSG, et al. J Am Acad Child Adolesc Psychiatry. 2009 May;48(5):484-500. doi: 10.1097/CHI.0b013e31819c23d0. J Am Acad Child Adolesc Psychiatry. 2009. PMID: 19318991 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical